[Skip to Content]
[Skip to Content Landing]
Editorial
January 2017

An Emerging Role for Imaging White Matter in the Preclinical Risk for Alzheimer Disease: Linking β-Amyloid to Myelin

Author Affiliations
  • 1Department of Psychology, University of Arizona, Tucson
  • 2Neuroscience Graduate Interdisciplinary Program, University of Arizona, Tucson
  • 3Physiological Sciences Graduate Interdisciplinary Program, University of Arizona, Tucson
  • 4Evelyn F. McKnight Brain Institute, University of Arizona, Tucson
  • 5Arizona Alzheimer’s Consortium, Tucson
JAMA Neurol. 2017;74(1):17-19. doi:10.1001/jamaneurol.2016.4123

Over the past 2 decades, advances in brain imaging have enhanced our ability to detect and evaluate the changes that occur as we age and in relation to the developing pathology of Alzheimer disease (AD). Because age is the greatest risk factor for developing Alzheimer dementia and the prevalence of AD is expected to grow rapidly,1 identifying the earliest effects of AD on the brain and the associated molecular mechanisms that lead to cognitive decline and dementia has profound implications for patient care and public health.1,2

×